CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer

NCT00075192 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostatic Neoplasms

Interventions

DRUG: CP-675,206 and leuprolide acetate and bicalutamide
DRUG: leuprolide acetate and bicalutamide

Sponsor

AstraZeneca